What is AKTS's current stock price?

AKTS (Aktis Oncology, Inc.) is currently trading at $20.31 with a market cap of $1.08B.

What sector is Aktis Oncology, Inc. in?

Aktis Oncology, Inc. (AKTS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is AKTS a good stock to buy?

Analysts have a Buy consensus on AKTS with a price target of $30.50. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

AKTS Aktis Oncology, Inc.

Healthcare

$20.31+0.00%OpenMarket Cap: $1.08B

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.22

P/S

180.14

EV/EBITDA

-13.47

DCF Value

$2.39

FCF Yield

-5.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

89.2%

Operating Margin

-924.0%

Net Margin

-754.9%

ROE

-130.3%

ROA

-7.9%

ROIC

-10.1%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$3.2M	$-18.3M	$—
Q4 null	$1.9M	$-15.1M	$—
FY null	$6.5M	$-63.7M	$—
Q4 null	$933.0K	$-12.1M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$30.50

Target (Median)

$30.50

Target Range

$30.00 - $31.00

1 Strong Buy5 Buy0 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-03-31

Trading Activity

Insider Trades

View All

ELI LILLY & Co10 percent owner

SellThu Jan 15

Latest News

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing TumorsGlobeNewsWire · Thu May 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.91

Aktis Oncology, Inc. operates as a clinical-stage oncology company that engages in the development of targeted radiopharmaceutical therapies for cancer treatment. The company offers a miniprotein radioconjugate platform to discover and develop radiopharmaceutical therapies that deliver the tumor-killing properties of radioisotopes. It offers Nectin-4, a miniprotein radioconjugate for the treatment of locally advanced or metastatic urothelial cancer. Its products include AKY-1189 to deliver a radioisotope to Nectin-4 expressing tumors for the treatment of metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and AKY-2519 to deliver radioisotope to B7-H3 CD276 expressing tumors targeting prostate, lung and other solid tumors. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is based in Boston, Massachusetts.